Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence

BACKGROUND: This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. METHODS: The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucle...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouvea, Maria da Penha Gomes, Moulaz, Isac Ribeiro, Gouveia, Thayná Martins, Lança, Karen Evelin Monlevade, Lacerda, Bárbara Sthefany de Paula, Thompson, Beatriz Paoli, Polese, Jéssica, de Lima, Marina Deorce, Ribeiro-Rodrigues, Rodrigo, Mill, José Geraldo, Valim, Valéria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Medicina Tropical - SBMT 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592100/
https://www.ncbi.nlm.nih.gov/pubmed/36287469
http://dx.doi.org/10.1590/0037-8682-0106-2022
Descripción
Sumario:BACKGROUND: This study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. METHODS: The serum antibody levels and clinical data from 73 healthcare workers with SARS-CoV-2 divided into seroconverted (n=51) and non-seroconverted (n=22) groups were assessed. The presence of specific anti-nucleocapsid (anti-N) IgM and IgG for SARS-CoV-2 was evaluated. IgG antibodies to the SARS-CoV-2 spike receptor-binding domain were used to confirm non-seroconversion in all negative anti-N. RESULTS: Four recurrent cases displayed mild symptoms and were non-seroconverted until the recurrence of symptoms. CONCLUSIONS: Undetectable anti-nucleocapsid IgM and IgG levels may be correlated with symptomatic COVID-19 recurrence.

Ejemplares similares